ALX-009
- Generic Name
- ALX-009
- Drug Type
- Biotech
- Unique Ingredient Identifier
- 2BP92KEU27
Dose Escalation Study of ALX-009 in Healthy Men and Cystic Fibrosis (CF) and Non-CF Bronchiectasis Patients
Phase 1
Terminated
- Conditions
- Cystic FibrosisBronchiectasis
- Interventions
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Alaxia SAS
- Target Recruit Count
- 92
- Registration Number
- NCT02598999
- Locations
- 🇫🇷
Eurofins Optimed, Grenoble, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath